Drug Search Results
More Filters [+]

Oseltamivir

Alternative Names: oseltamivir, tamiflu
Latest Update: 2025-01-07
Latest Update Note: Clinical Trial Update

Product Description

Oseltamivir is a prodrug of oseltamivir carboxylate (Ro 64-0802, GS4071), a potent and selective inhibitor of the neuraminidase glycoprotein essential for replication of influenza A and B viruses.  (Sourced from: https://pubmed.ncbi.nlm.nih.gov/11270942/)

Mechanisms of Action: NEU Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Oseltamivir

Countries in Clinic: Australia, Belgium, Canada, China, Colombia, Croatia, Czech Republic, Estonia, Finland, France, Germany, Ghana, Hungary, India, Indonesia, Ireland, Israel, Italy, Japan, Nepal, Netherlands, New Zealand, Pakistan, Portugal, Romania, Saudi Arabia, Serbia, Slovenia, South Africa, Spain, Switzerland, United Kingdom, United States, Vietnam

Active Clinical Trial Count: 15

Highest Development Phases

Phase 3: COVID-19|Influenza, Human|Pneumonia|Severe Acute Respiratory Syndrome

Phase 1: Healthy Volunteers|Kidney Diseases|Kidney Failure, Chronic|Respiratory Insufficiency

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

RECOVERY

P3

Recruiting

Severe Acute Respiratory Syndrome|COVID-19

2026-06-30

REMAP-CAP

P3

Recruiting

Influenza, Human|COVID-19|Pneumonia

2026-02-01

ZX-7101A-208

P1

Completed

Healthy Volunteers

2023-12-05

CTR20230077

P1

Completed

Influenza, Human

2023-09-11

Recent News Events